{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:07:31Z","timestamp":1790345251554,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is growing evidence that inflammation is associated with development and progression of cardiovascular disease (CVD). The extent of physician awareness of this evidence, and its impact on clinical care, is unknown. Therefore, our aim was to investigate and characterize the perceptions and clinical practices of HCPs with respect to inflammation when treating patients with atherosclerotic CVD (ASCVD)\u2009+\u2009chronic kidney disease (CKD) stage 3\u20134 or heart failure (HF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a qualitative research study involving semi-structured, 1-hour Zoom interviews (including open- and close-ended questions) conducted from February-April 2024. Eligible HCPs were cardiologists, nephrologists, or general practitioners with \u22655 and \u226430 years of post-graduate clinical experience; working in France, Denmark, the Netherlands, Spain, Sweden, and Switzerland; who had managed \u226510 patients with ASCVD\u2009+\u2009CKD or HF in the previous 3 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most of the 62 HCPs included in the study (84%) acknowledged the theoretical importance of inflammation in progression of ASCVD\u2009+\u2009CKD or HF. However, only 17 (27% of the 62) routinely tested for high-sensitivity C-reactive protein (hsCRP) due to limited awareness of the clinical implications of inflammation in CVD and the lack of consistently proven interventions. If hsCRP is assessed, HCPs cannot alter their patient management in response to the findings due to a lack of treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study presents the perceptions and practices of a sample of HCPs. Because of limited evidence for the efficacy of interventions and the incomplete understanding of the role of inflammation in CVD, inflammation remains a neglected treatment target in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1672079","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:56:58Z","timestamp":1790344618000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Inflammation across the spectrum of cardiovascular disease: healthcare physician perceptions and practices in six European countries"],"prefix":"10.3389","volume":"13","author":[{"given":"Guiomar","family":"Mendieta","sequence":"first","affiliation":[{"name":"Department of Cardiology, Hospital de la Santa Creu I Sant Pau","place":["Barcelona, Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital\u2013Herlev & Gentofte","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Vukmirica","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henna","family":"Cederberg-Tamminen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmundo","family":"Erazo-Tapia","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Casciano","sequence":"additional","affiliation":[{"name":"Certara","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Read","sequence":"additional","affiliation":[{"name":"Certara","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Sostar","sequence":"additional","affiliation":[{"name":"Certara","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Mathias","sequence":"additional","affiliation":[{"name":"Certara","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April Dominique","family":"Ocampo","sequence":"additional","affiliation":[{"name":"Certara","place":["Makati City, Philippines"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bernardini","sequence":"additional","affiliation":[{"name":"Certara","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"Cornel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Radboud University Medical Center","place":["Nijmegen, Netherlands"]},{"name":"Department of Cardiology, Northwest Clinics","place":["Alkmaar, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1093\/eurheartj\/ehad583","article-title":"Economic burden of cardiovascular diseases in the European union: a population-based cost study","volume":"44","author":"Luengo-Fernandez","year":"2023","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.clinthera.2023.09.020","article-title":"Global trends in atherosclerotic cardiovascular disease","volume":"45","author":"Nedkoff","year":"2023","journal-title":"Clin Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global burden of cardiovascular diseases and risks, 1990\u20132022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/s0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.123.066213","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary high-risk patients with statin intolerance","volume":"149","author":"Ridker","year":"2024","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jacc.2023.05.035","article-title":"C-reactive protein and risk of incident heart failure in patients with cardiovascular disease","volume":"82","author":"Burger","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.31083\/j.rcm.2020.04.154","article-title":"Epidemiology and pathogenesis of heart failure with preserved ejection fraction","volume":"21","author":"Nair","year":"2020","journal-title":"Rev Cardiovasc Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1327205","DOI":"10.3389\/fmed.2023.1327205","article-title":"Systemic inflammation among adults with diagnosed and undiagnosed cardiometabolic conditions: a potential missed opportunity for cardiovascular disease prevention","volume":"10","author":"Mainous","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B11","year":"2024"},{"key":"B12","year":"2022"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"B14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.5334\/gh.1382","article-title":"Awareness and perceptions towards the role of systemic inflammation and high-sensitivity C-reactive protein as a biomarker in atherosclerotic cardiovascular disease and chronic kidney disease: the multinational FLAME-ASCVD survey amongst cardiologists","volume":"19","author":"Marx","year":"2024","journal-title":"Glob Heart"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2024g78qxr0a","article-title":"Role of inflammation and high-sensitivity C-reactive protein in atherosclerotic cardiovascular disease and CKD: a survey of nephrologists","volume":"35","author":"Perkovic","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1161\/01.cir.101.15.1767","article-title":"Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1161\/01.Cir.0000104566.10178.Af","article-title":"Blood pressure, C-reactive protein, and risk of future cardiovascular events","volume":"108","author":"Blake","year":"2003","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1136\/heartjnl-2018-314216","article-title":"Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies","volume":"105","author":"Jayedi","year":"2019","journal-title":"Heart"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e012638","DOI":"10.1161\/JAHA.119.012638","article-title":"hsCRP level and the risk of death or recurrent cardiovascular events in patients with myocardial infarction: a healthcare-based study","volume":"8","author":"Carrero","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.119.13642","article-title":"Effects of interleukin-1\u03b2 inhibition on blood pressure, incident hypertension, and residual inflammatory risk","volume":"75","author":"Rothman","year":"2020","journal-title":"Hypertension"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","article-title":"Inhibition of interleukin-1\u03b2 by canakinumab and cardiovascular outcomes in patients with chronic kidney disease","volume":"71","author":"Ridker","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/s0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.2147\/jir.S462848","article-title":"Association of systemic inflammation level on admission with total and cardiovascular\u2014specific death in heart failure with preserved ejection fraction: a large multi\u2014center retrospective longitudinal study","author":"Lai","year":"2024","journal-title":"J Inflamm Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","article-title":"Inflammation in obesity-related HFpEF: the STEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/mca.0000000000001220","article-title":"Meta-analysis of the effect of colchicine on C-reactive protein in patients with acute and chronic coronary syndromes","volume":"34","author":"Alam","year":"2023","journal-title":"Coron Artery Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"107575","DOI":"10.1016\/j.phrs.2024.107575","article-title":"GWAS of CRP response to statins further supports the role of APOE in statin response: a GIST consortium study","volume":"212","author":"Magavern","year":"2025","journal-title":"Pharmacol Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s12872-024-04022-7","article-title":"Dapagliflozin, inflammation and left ventricular remodelling in patients with type 2 diabetes and left ventricular hypertrophy","volume":"24","author":"Dihoum","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12933-024-02548-w","article-title":"Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study","volume":"24","author":"Madsen","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jamacardio.2024.4613","article-title":"Finerenone in women and men with heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Chimura","year":"2025","journal-title":"JAMA Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European association of preventive cardiology (EAPC)","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/cir.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) endorsed by the European association for cardio-thoracic surgery (EACTS)","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.rec.2022.05.005","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC","volume":"75","author":"McDonagh","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","article-title":"Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"key":"B41","year":""},{"key":"B42","doi-asserted-by":"publisher","first-page":"e031251","DOI":"10.1161\/jaha.123.031251","article-title":"Differential response to interleukin-1 blockade with anakinra on cardiorespiratory fitness in patients with heart failure with preserved ejection fraction stratified according to left ventricular ejection fraction","volume":"12","author":"Golino","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"B43","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cardfail.2023.10.024","article-title":"Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation","volume":"30","author":"Petrie","year":"2024","journal-title":"J Card Fail"},{"key":"B44","year":"2024"},{"key":"B45","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1136\/heartjnl-2013-303640","article-title":"Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score","volume":"99","author":"Dorresteijn","year":"2013","journal-title":"Heart"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jacc.2025.08.047","article-title":"Inflammation and cardiovascular disease: 2025 ACC scientific statement: a report of the American College of Cardiology","volume":"87","author":"Mensah","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/mca.0000000000001198","article-title":"Inflammation in coronary artery disease-clinical implications of novel HDL-cholesterol-related inflammatory parameters as predictors","volume":"34","author":"Guo","year":"2023","journal-title":"Coron Artery Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e007405","DOI":"10.1161\/circheartfailure.120.007405","article-title":"Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document","volume":"13","author":"Ammirati","year":"2020","journal-title":"Circ Heart Fail"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1672079\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:56:59Z","timestamp":1790344619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1672079\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":48,"alternative-id":["10.3389\/fcvm.2026.1672079"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1672079","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1672079"}}